Deregistration notice
Open the filing on sec.gov
Apogee Therapeutics, Inc. (APGE)
APGE · Biological Products, (No Diagnostic Substances) · Waltham, MA · filing with the SEC since 2023
The companyfiscal 2025, as filed
Revenuen/a
Net income-$256M-40.5%
Earnings per share$-4.22-27.9%
Operating cash flow-$227M-32.9%
Cash$132M-7.2%
Debtn/a
Shareholders’ equityn/a
Shares, diluted60.7M+10.0%
Return on equityn/a
The recordfrom its filings
Filings in 2026109
Newest filingSep 14 · 15-12G
Annual reportMar 2, 2026
Quarterly reportAug 10, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$174M
Insider buys, 12 months$0.00
Patents granted1
Filer categoryLarge accelerated filer
Trailing twelve months to Jun 2026Net income -$294MCash from operations -$244Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Activist holder update, amended
Open the filing on sec.gov
Delisting notice from the exchange
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.